Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Other financing activities (2019 - 2024)

Dna X filings provide 4 years of Other financing activities readings, the most recent being $472000.0 for Q2 2024.

  • On a quarterly basis, Other financing activities rose 31.84% to $472000.0 in Q2 2024 year-over-year; TTM through Jun 2024 was $1.5 million, a 25.55% decrease, with the full-year FY2023 number at $1.5 million, down 3.55% from a year prior.
  • Other financing activities hit $472000.0 in Q2 2024 for Dna X, up from $324000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.0 million in Q4 2022 to a low of $253000.0 in Q1 2022.
  • Median Other financing activities over the past 3 years was $324000.0 (2024), compared with a mean of $430571.4.
  • The widest YoY moves for Other financing activities: up 31.84% in 2024, down 4.85% in 2024.
  • Dna X's Other financing activities stood at $1.0 million in 2022, then plummeted by 65.48% to $358000.0 in 2023, then surged by 31.84% to $472000.0 in 2024.
  • The last three reported values for Other financing activities were $472000.0 (Q2 2024), $324000.0 (Q1 2024), and $358000.0 (Q2 2023) per Business Quant data.